MMM 3M (MMM) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000066740
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
931
13F, latest reported quarter
Conversions, 180 days
13
Codes C/M, not in net · $9.9M priced
What the filings say about MMM
Insiders, 180 days
-$4.3M net sold
5 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
0 bought · 3 sold
Latest: sale, 2026-04-28
Planned sales (Form 144), 90 days
$663.4K
1 notice
3M insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, 3M CO insiders sold a net $4.3M of stock across 219 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 9, 2026.
- The trade is 25.9% of the 14,034 shares held after it.
- 4 other insiders sold within 30 days.
- 931 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Group President Chavez Rodriguez Beatriz Karina sold about $663.4K of MMM on Aug 5, 2026; 4 other insiders sold within 30 days and 931 funds added in the latest 13F quarter.Context
- 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on May 23, 2025.
- The trade is 15.7% of the 50,056 shares held after it.
- 4 other insiders sold within 30 days.
- 931 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President Banovetz John Patrick sold about $1.3M of MMM on Jul 23, 2026; 4 other insiders sold within 30 days and 931 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Feb 11, 2026.
- The trade is 35.3% of the 2,615 shares held after it.
- 4 other insiders sold within 30 days.
- 931 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Sr Vice President & CAO Reinseth Theresa E sold about $156.5K of MMM on Jul 23, 2026; 4 other insiders sold within 30 days and 931 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (4 buys, 2 sales), the last on Aug 7, 2025.
- +24.3% median (+21.8% mean) 90-day return after 4 previous buys.
- The trade is 70.3% of the 6,971 shares held after it.
- 4 other insiders sold within 30 days.
- 931 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Group President Goralski Christian T JR sold about $835.6K of MMM on Jul 22, 2026; 4 other insiders sold within 30 days and 931 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on May 20, 2025.
- The trade is 17.5% of the 43,779 shares held after it.
- 4 other insiders sold within 30 days.
- 931 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Chief Legal Off & Secret Rhodes Kevin H sold about $1.3M of MMM on Jul 22, 2026; 4 other insiders sold within 30 days and 931 funds added in the latest 13F quarter.219 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$4.3M over 180 days
-$663.4K over 90 days
below 76% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
931 funds bought in last quarter
more than 98% of Medical Devices
Revenue
+1.5% year over year
below 74% of Medical Devices
Margin
13.0% net margin
more than 85% of Medical Devices
Buybacks
$3.2B repurchased, FY to 2026-09-30
more than 98% of Medical Devices
Short interest
1.9% of the float short (float per yahoo 2026-10-26) · 3.1 days to cover · settled 2026-09-30
below 66% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch MMM
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+2.1%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns MMM: institutional holders (13F)
13F holdings, latest reported quarter
45,048,766 sh
$7.3B
39,432,727 sh
$6.4B
34,065,039 sh
$5.5B
27,828,966 sh
$4.5B
11,957,078 sh
$1.9B
Congress trades in MMM
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-04-28 · disclosed 21 days later
$1,001 - $15,000
Sold 2026-02-04 · disclosed 36 days later
$1,001 - $15,000
Sold 2026-02-02 · disclosed 38 days later
$1,001 - $15,000
Sold 2025-12-18 · disclosed 28 days later
$1,001 - $15,000
Sold 2025-11-13 · disclosed 28 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
MMM planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Chavez Rodriguez Beatriz Karina
Filed 2026-08-05
$663.4K
Banovetz John Patrick
Filed 2026-07-23
$1.3M
Reinseth Theresa E
Filed 2026-07-23
$156.5K
Rhodes Kevin H
Filed 2026-07-22
$1.3M
Goralski Christian T JR
Filed 2026-07-22
$835.6K
MMM mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Invesco Dow Jones Industrial Average Dividend ETF
$20.1M position · as of 2026-07-31
4.1%
First Trust Dow 30 Equal Weight ETF
$10.3M position · as of 2026-06-30
3.4%
Calamos Phineus Long/Short Fund
$35.3M position · as of 2026-07-31
3.2%
Victory Pioneer Equity Income Fund
$24.7M position · as of 2026-07-31
3.0%
Victory Pioneer Equity Income VCT Portfolio
$2.1M position · as of 2026-06-30
2.9%
Eaton Vance Focused Value Opportunities Fund
$1.9M position · as of 2026-05-31
2.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · (1)
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2020
$20.7M
$15.7M
$5.8M
+3%
+10%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $4.3M sold by insiders over 180 days, 931 funds added last quarter, $663.4K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
MMM financials
Revenue growth
+1.5%
XBRL, annual
Net margin
13.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$25.2B
four quarters, 2025-10-01 to 2026-09-30
Revenue, TTM MMM
| FY Dec 2025 | $24.9B |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | $34.2B |
| FY Dec 2021 | $35.4B |
| Sep 2026 | $6.6B |
| Jun 2026 | $6.5B |
| Mar 2026 | $6.0B |
| Dec 2025 | $6.1B |
| Sep 2025 | $6.5B |
| Jun 2025 | $6.3B |
| Mar 2025 | $6.0B |
| Dec 2024 | $6.0B |
At each fiscal year end
Single quarter
Net margin, TTM
+14.0%
net income over revenue, 2025-10-01 to 2026-09-30
Net margin, TTM MMM
| FY Dec 2025 | +13.0% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +16.9% |
| FY Dec 2021 | +16.7% |
| Sep 2026 | +20.9% |
| Jun 2026 | +14.4% |
| Mar 2026 | +10.8% |
| Dec 2025 | +9.4% |
| Sep 2025 | +12.8% |
| Jun 2025 | +11.4% |
| Mar 2025 | +18.7% |
| Dec 2024 | +12.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$2.7B
operating cash flow minus capex, 2025-10-01 to 2026-09-30
Free cash flow, TTM MMM
| FY Dec 2025 | $1.4B |
| FY Dec 2024 | $638.0M |
| FY Dec 2023 | $5.1B |
| FY Dec 2022 | $3.8B |
| FY Dec 2021 | $5.9B |
| Sep 2026 | $230.0M |
| Jun 2026 | $763.0M |
| Mar 2026 | $349.0M |
| Dec 2025 | $1.3B |
| Sep 2025 | $1.5B |
| Jun 2025 | -$1.2B |
| Mar 2025 | -$315.0M |
| Dec 2024 | $1.5B |
At each fiscal year end
Single quarter
Debt to equity
3.63x
long-term 2026-09-30 plus current 2026-09-30; equity 2026-09-30
Debt to equity MMM
| FY Dec 2025 | 2.68x |
| FY Dec 2024 | 3.40x |
| FY Dec 2023 | 3.34x |
| FY Dec 2022 | 1.08x |
| FY Dec 2021 | 1.15x |
| Sep 2026 | 3.63x |
| Jun 2026 | 4.25x |
| Mar 2026 | 3.85x |
| Dec 2025 | 2.68x |
| Sep 2025 | 2.72x |
| Jun 2025 | 3.06x |
| Mar 2025 | 3.02x |
| Dec 2024 | 3.40x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.24x
TTM operating cash flow over long-term 2026-09-30 plus current 2026-09-30
Cash flow to debt MMM
| FY Dec 2025 | 0.18x |
| FY Dec 2024 | 0.14x |
| FY Dec 2023 | 0.42x |
| FY Dec 2022 | 0.35x |
| FY Dec 2021 | 0.43x |
| Sep 2026 | 0.24x |
| Jun 2026 | 0.39x |
| Mar 2026 | 0.24x |
| Dec 2025 | 0.18x |
| Sep 2025 | 0.20x |
| Jun 2025 | -0.08x |
| Mar 2025 | 0.07x |
| Dec 2024 | 0.14x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+80.8%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on equity MMM
| FY Dec 2025 | +76.1% |
| FY Dec 2024 | +96.5% |
| FY Dec 2023 | -71.6% |
| FY Dec 2022 | +38.8% |
| FY Dec 2021 | +42.4% |
| Sep 2026 | +80.8% |
| Jun 2026 | +82.8% |
| Mar 2026 | +72.1% |
| Dec 2025 | +76.1% |
| Sep 2025 | +73.4% |
| Jun 2025 | +96.0% |
| Mar 2025 | +93.5% |
| Dec 2024 | +96.5% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+9.2%
TTM net income over average of 2025-09-30 and 2026-09-30
Return on assets MMM
| FY Dec 2025 | +8.4% |
| FY Dec 2024 | +9.2% |
| FY Dec 2023 | -14.4% |
| FY Dec 2022 | +12.4% |
| FY Dec 2021 | +12.5% |
| Sep 2026 | +9.2% |
| Jun 2026 | +8.2% |
| Mar 2026 | +7.4% |
| Dec 2025 | +8.4% |
| Sep 2025 | +8.7% |
| Jun 2025 | +9.7% |
| Mar 2025 | +9.2% |
| Dec 2024 | +9.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+22.2%
operating income after a 19.2% effective tax rate, over long-term 2026-09-30 plus current 2026-09-30 plus average of 2025-09-30 and 2026-09-30 minus cash
Return on invested capital MMM
| FY Dec 2025 | +24.0% |
| FY Dec 2024 | +26.4% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +14.6% |
| FY Dec 2021 | +20.8% |
| Sep 2026 | +22.2% |
| Jun 2026 | +25.4% |
| Mar 2026 | +24.9% |
| Dec 2025 | +24.0% |
| Sep 2025 | +26.1% |
| Jun 2025 | +25.8% |
| Mar 2025 | +25.8% |
| Dec 2024 | +26.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+16.8%
operating income (EBIT proxy) over average of 2025-09-30 and 2026-09-30 minus current liabilities
Return on capital employed MMM
| FY Dec 2025 | +16.3% |
| FY Dec 2024 | +15.1% |
| FY Dec 2023 | n/a |
| FY Dec 2022 | +11.7% |
| FY Dec 2021 | +19.0% |
| Sep 2026 | +16.8% |
| Jun 2026 | +17.2% |
| Mar 2026 | +16.8% |
| Dec 2025 | +16.3% |
| Sep 2025 | +16.9% |
| Jun 2025 | +16.2% |
| Mar 2025 | +13.6% |
| Dec 2024 | +15.1% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
25.75x
close 2026-10-26 over four quarters of diluted EPS, 2025-10-01 to 2026-09-30
P/E, trailing MMM
| FY Dec 2025 | 26.68x |
| FY Dec 2024 | 17.10x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 9.83x |
| FY Dec 2021 | 14.68x |
| Sep 2026 | 24.46x |
| Jun 2026 | 28.76x |
| Mar 2026 | 27.98x |
| Dec 2025 | 26.68x |
| Sep 2025 | 24.79x |
| Jun 2025 | 21.17x |
| Mar 2025 | 18.54x |
| Dec 2024 | 17.10x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$102.1B
market value at close 2026-10-26 on 2026-09-30 shares, plus long-term 2026-09-30 plus current 2026-09-30, minus cash 2017-03-31
Enterprise value MMM
| FY Dec 2025 | $95.5B |
| FY Dec 2024 | $81.2B |
| FY Dec 2023 | $64.3B |
| FY Dec 2022 | $69.2B |
| FY Dec 2021 | $100.8B |
| Sep 2026 | $97.6B |
| Jun 2026 | $93.9B |
| Mar 2026 | $86.1B |
| Dec 2025 | $95.5B |
| Sep 2025 | $92.9B |
| Jun 2025 | $92.1B |
| Mar 2025 | $90.3B |
| Dec 2024 | $81.2B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+3.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield MMM
| FY Dec 2025 | +1.6% |
| FY Dec 2024 | +0.9% |
| FY Dec 2023 | +10.0% |
| FY Dec 2022 | +6.9% |
| FY Dec 2021 | +6.8% |
| Sep 2026 | +3.2% |
| Jun 2026 | +4.8% |
| Mar 2026 | +2.7% |
| Dec 2025 | +1.6% |
| Sep 2025 | +1.9% |
| Jun 2025 | -2.4% |
| Mar 2025 | -0.1% |
| Dec 2024 | +0.9% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
3.58x
P/E over trailing EPS growth of 7%: four quarters to 2026-09-30 against the four to 2025-09-30
PEG, trailing MMM
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 12.44x |
| FY Dec 2021 | 1.73x |
| Sep 2026 | 3.40x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 0.07x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $24.9B | $24.6B | $32.7B | $34.2B |
| Operating income | $4.6B | $4.8B | -$10.7B | $4.4B |
| Net income | $3.2B | $4.2B | -$7.0B | $5.8B |
| EPS (diluted) | 6.00 | 7.55 | -12.63 | 10.18 |
| Operating cash flow | $2.3B | $1.8B | $6.7B | $5.6B |
| Long-term debt | $10.9B | $11.1B | $13.1B | $14.0B |
| Buybacks | $3.3B | $1.8B | $33.0M | $1.5B |
| Dividends paid | $1.6B | $2.0B | $3.3B | $3.4B |
SEC XBRL, fiscal years, as known on 2026-10-28
MMM Stock Sonar score 6/7 axes
Find similar shapesCompareMMM ranks highest on profitability (90th percentile) and risk and compliance (65th), and lowest on insider conviction (11th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
MMM filings, in plain words
Are 3M insiders buying or selling MMM?
In the 180 days to 2026-10-28, 3M insiders were net sellers, a net $4.3M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded MMM?
Yes. In the year to 2026-10-28, 0 House members disclosed buying MMM and 3 House members disclosed selling it; the latest on record is a sale by Josh Gottheimer dated 2026-04-28.
Are there planned insider sales of MMM?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $663.4K of stock; the latest, by Chavez Rodriguez Beatriz Karina, was filed 2026-08-05.
Read the full summary
In the 180 days to 2026-10-28, 3M insiders were net sellers of MMM, a net $4.3M across purchases and sales reported on Form 4 by 5 sellers. None of the 5 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 0 members of Congress disclosed buying MMM and 3 members disclosed selling it; the latest on record is a sale by Josh Gottheimer dated 2026-04-28. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $663.4K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
